STANDARD BIOTOOLS INC. (LAB)
Health Care · life science tools and services · NASDAQ
Standard BioTools provides specialized proteomics and genomics research platforms to accelerate drug discovery, currently undergoing a strategic transition toward a merger with Treeline Biosciences.
What STANDARD BIOTOOLS INC. does
Standard BioTools provides life science research tools, including instrumentation, consumables, and services, designed to assist biomedical researchers in drug discovery and translational research. Its portfolio includes platforms for proteomics and genomics, such as CyTOF and Hyperion, which allow researchers to generate high-content data across diverse therapeutic areas. The company is currently undergoing significant strategic transformation, including the divestiture of its SomaScan business and a pending merger with Treeline Biosciences.
Recent developments
Standard BioTools is in the process of merging with Treeline Biosciences, with the transaction anticipated to close before the end of 2026. The company recently received a $30 million early buyout from Illumina related to contingent payments from the previous SomaScan business acquisition and has initiated the divestiture of its Mass Cytometry business. Due to these ongoing corporate transitions, the company has withdrawn its full-year 2026 revenue guidance.
From STANDARD BIOTOOLS INC.'s filing of 2026-08-05.
Themes: drug discovery research tools, proteomics, genomics, spatial biology, corporate restructuring
Fundamentals
- Price$0.6373 as of 2026-10-20 close
- Market cap$250M as of 2026-08-03 (share count; price 2026-10-20)
- 1-year return-50.2% 2025-10-20 close $1.28 → 2026-10-20 close $0.6373
- P/E2.90 as of 2026-10-20
- Net margin-87.8% FY2025, SEC XBRL
- Gross margin+49.9% FY2025, SEC XBRL
- ROE-17.7% FY2025, SEC XBRL
- ROICn/a No figure: its pre-tax income was zero or negative, so there is no tax rate to apply.
- Debt / equityn/a No figure: its filing tags none of the debt lines we read, which is not evidence of zero debt.
- Revenue growth (YoY)-6.2% FY2025, SEC XBRL
- Revenue CAGR (3y)-4.5% SEC XBRL
- Beta1.46 as of 2026-09-02
- Last reported earnings2026-08-05 SEC EDGAR Form 8-K (Item 2.02)
How LAB compares in its sector
- price-to-earnings ratiobottom 10% 181 covered Health Care peers, as of 2026-10-20
- net profit marginmiddle range 430 covered Health Care peers, as of 2026-09-02
- operating marginmiddle range 417 covered Health Care peers, as of 2026-09-02
- gross marginmiddle range 189 covered Health Care peers, as of 2026-09-02
- return on equitymiddle range 510 covered Health Care peers, as of 2026-09-02
- 3-year revenue CAGRbottom 25% 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)middle range 494 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Quarterly results
| Quarter | Revenue | Gross profit | Operating income | Net income | Diluted EPS | Operating cash flow | Capex |
|---|---|---|---|---|---|---|---|
| Q2 FY2026 2026-06-30 | $20M | $11M | -$25M | -$27M | -$0.07 | -$10M† | $344000† |
| Q1 FY2026 2026-03-31 | $21M | $11M | -$12M | $127M | $0.33 | -$47M | $570000 |
| Q4 FY2025 2025-12-31 | $24M† | $11M† | -$25M† | $19M† | $0.05† | -$1M† | $476000† |
| Q3 FY2025 2025-09-30 | $20M | $9M | -$33M | -$35M | -$0.09 | -$22M† | $886000† |
| Q2 FY2025 2025-06-30 | $22M | $11M | -$26M | -$33M | -$0.09 | -$21M† | $2M† |
| Q1 FY2025 2025-03-31 | $20M | $11M | -$27M | -$26M | -$0.07 | -$30M | $5M |
| Q4 FY2024 2024-12-31 | $25M† | $11M† | -$26M† | -$34M† | -$0.08† | -$14M† | $3M† |
| Q3 FY2024 2024-09-30 | $22M | $12M | -$27M | -$27M | -$0.07 | -$28M† | $2M† |
† Not filed as a discrete quarter: derived from the company's own year-to-date figures (for example the fourth quarter as the fiscal year minus the first nine months). A derived per-share figure is approximate, because the share count moves within the year.
Balance sheet at 2026-06-30
- Cash and equivalents$270M
- Short-term investments$207M
- Total debtnot shown the filing tags none of the debt lines we read — not evidence of zero debt
From the company's own SEC 10-Q and 10-K filings (XBRL), re-read every week. Figures in US dollars as filed; informational only — not financial advice.
How STANDARD BIOTOOLS INC. looks technically
STANDARD BIOTOOLS INC. (LAB) is trading 33.0% below its 200-day average, the long-term trend line — a long-term downtrend. Its 50-day average crossed below its 200-day average about 154 trading days ago — a "death cross", a bearish long-term signal. There is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 18, below the 25 that marks a real trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 40, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bearish about 10 trading days ago (its momentum flipped negative). It made a new 20-day low about 5 trading days ago. It is 3.1% above its 52-week low (its lowest price of the past year).
Trend
8
| Distance from the 200-day | it is trading 33.0% below its 200-day average, the long-term trend line — a long-term downtrend | -33.0% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $0.695 | $0.695 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $0.9513 | $0.9513 |
| Swing structure | each recent peak has been lower than the one before it and each dip deeper — the pattern chart-watchers call a downtrend, which describes where price has already been and not where it goes next | lower highs and lower lows |
| Last swing turn | its last significant turn was a swing high 102 calendar days ago — the swings before that are what the structure reading is measured on | 102 sessions |
| Wave structure | its recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now in leg 5 of five; the labelling fails if price closes above 0.97. It is the only labelling that fits, though not with textbook proportions, and it describes the swings already printed, not what comes next. | possible downward five-wave sequence, in wave 5 (atypical proportions) |
| Since the 50/200 cross | its 50-day average crossed below its 200-day average about 154 trading days ago — a "death cross", a bearish long-term signal | 154 sessions |
| Trend strength (14-day ADX) | there is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 18, below the 25 that marks a real trend) | 18.3 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 40, neither overbought (above 70) nor oversold (below 30) | 39.8 |
|---|---|---|
| Position in its 14-day range | it is trading near the bottom of its 14-day range ($0.618 to $0.8) — its "stochastic" reading is 11 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 10.6 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bearish about 10 trading days ago (its momentum flipped negative) | 10 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $1.72 | $1.72 |
|---|---|---|
| From the 52-week high | it is 62.9% below its 52-week high (its highest price of the past year) | -63.0% |
| Above the 52-week low | it is 3.1% above its 52-week low (its lowest price of the past year) | +3.1% |
| Below the 52-week high | it is 62.9% below its highest point of the past year | 63.0% |
| Since a 20-day breakout | it made a new 20-day low about 5 trading days ago | 5 sessions |
| Since a 55-day breakout | it made a new 55-day low about 5 trading days ago | 5 sessions |
| All-time high | its highest closing price on record is $49.46 (set on 2014-02-27) | $49.46 |
| Given back of the 52-week move | over the past year its closes ranged ($0.63 to $1.68), and it has recovered essentially none of its fall from last year’s high — 1% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $1.28 to $1.31. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 0.7% |
| From the all-time high | it is 98.7% below its all-time high | -98.7% |
| Nearest price level | it is trading 52.7% below a resistance level at $0.9733 — a price it turned at three times since 2025-04-07, most recently on 2026-07-10. Since 2024-10-21 it has 0 such levels below the current price and 11 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | +52.7% |
| All-time low | its lowest closing price on record is $0.618 (set on 2026-10-20) | $0.618 |
| Above the all-time low | it is 3.1% above its all-time low | +3.1% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are about average versus its own recent 6-month history | 58th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.0395 between its high and its low — about 6.2% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.0395 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $0.61 and $0.78 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $0.61 – $0.7 – $0.78 |
| Typical daily range (% of price) | its price moves about 6.2% in a typical session — more volatile than most companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 6.2% |
| Stretch from the 200-day average | it is trading 7.9 daily ranges below its 200-day average price (33.0% below it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 7.9 daily ranges below its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.53× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | not available for this company yet | n/a |
Candlestick patterns
3
| Since a doji | 5 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 5 sessions ago |
|---|---|---|
| Since a bullish engulfing | 3 sessions ago it opened below the previous session's close and finished above that session's open — a "bullish engulfing" pair, where one up day more than undid the down day before it | 3 sessions ago |
| Since a bearish engulfing | 6 sessions ago it opened above the previous session's close and finished below that session's open — a "bearish engulfing" pair, where one down day more than undid the up day before it | 6 sessions ago |
Price gaps
2
| Gap at the open | it opened on 2026-10-20 1.9% below the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | -1.9% |
|---|---|---|
| Gap filled | a 3.0% gap down opened on 2026-10-14 has been "filled" 4 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 4 sessions ago |
Price streaks
1
| Closing streak | it closed lower in its latest session, after a session that did not close lower — a single down day rather than a run | 1 session down |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 18.2 percentage points (the stock lost 17.2% while the market gained 1.0%) | -18.2% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 28.7 percentage points (the stock lost 25.0% while the market gained 3.6%) | -28.7% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 42.8 percentage points (the stock lost 34.3% while the market gained 8.5%) | -42.8% |
| vs market, 12 months | over the past 12 months this stock lagged the market by 64.8 percentage points (the stock lost 50.2% while the market gained 14.6%) | -64.8% |
Signal agreement
2
| Bullish technical signals | 1 of the 9 technical signals we can compute for it is currently in a bullish state: near the bottom of its 14-day range (oversold) — these describe past price behaviour, not a forecast | 1 of 9 |
|---|---|---|
| Bearish technical signals | 5 of the 9 technical signals we can compute for it are currently in a bearish state: a "death cross" — its 50-day average is below its 200-day, trading below its 200-day average, MACD momentum is negative, lagging the market over 6 months, trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 5 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 9.6% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-14 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is thick, spanning 14.9% of the share price, which is taken to mean a barrier that has held for a while and takes effort to cross. | -9.6% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 32% below the average price paid so far this year, so the typical buyer over that stretch is under water. That average is $0.9311 — a volume-weighted average of daily closes over 200 sessions, not a true tick-by-tick VWAP. | -31.6% |
|---|---|---|
| Vs the average paid since it last reported | the price is 9% below the average price paid since it last reported on 2026-08-05 (its 10-Q), so the typical buyer over that stretch is under water. That average is $0.6981 — a volume-weighted average of daily closes over 54 sessions, not a true tick-by-tick VWAP. | -8.7% |
Price levels it has turned at before
LAB last closed at $0.6373 on 2026-10-20. Since 2024-10-21 it has turned at 0 prices below its last close and 11 above; the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $0.9733 | Resistance | 52.7% above the last close | turned there three times · 2025-04-07 to 2026-07-10 |
| $1.15 | Resistance | 80.5% above the last close | turned there twice · 2025-07-01 to 2025-08-14 |
| $1.20 | Resistance | 88.3% above the last close | turned there twice · 2025-07-21 to 2025-09-03 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now in leg 5 of five.
This labelling fails — stops being a possible reading at all — if it closes above $0.97.
It is the only labelling that fits these swings, though its proportions are not the textbook ones. It was chosen from 3 labellings that survived the rules, counting shorter readings of the same bars.
On past moves of this shape the leg has usually ended somewhere between $0.0477 and $0.6177 — that is where it has tended to end if the count holds, not a forecast of where the price goes.
This labelling was already in place when we began recording count changes on 2026-08-13, so how long it has stood is not something we can say yet.
Read from daily closes as of 2026-10-20.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading below the 200-day moving average · Trading below the 50-day moving average · Pulled back from the 12-month high · trendless / choppy (low ADX) · Near the all-time low · lagging the market | Learn: moving average · golden cross · adx · rsi · macd · breakout · fifty two week high low
Based on daily closing prices as of 2026-10-20. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Mean price target$1.35 range $1.35 – $1.35
Analyst estimates, as of 2026-10-17. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Key risks (from latest filing)
["The company has a history of losses and net loss from continuing operations; future profitability is uncertain.","The pending merger with Treeline Biosciences and recent divestitures create significant organizational transition and execution risk.","Revenue is sensitive to capital-constrained end-markets and fluctuations in research spending within academia and biopharma."]
Insider activity (SEC Form 4)
No open-market insider purchases or sales are on record for LAB — recent Form 4 activity was compensation-related (awards, option exercises, or tax withholding), not open-market buying or selling.
View full insider trading history → View SEC Form 3/4/5 filingsOnly open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
6 institutional 13F filers reported holding LAB as of 2026-06-30 (quarter-end position, filed within 45 days).
- Distinct 13F filers 6
- Reported shares held 74,197,242
- Reported value $61,042,073
reported quarterly holdings change (2026-03-31 → 2026-06-30): 1 new, 1 increased, 3 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Ask about LAB's institutional holders → See what each manager we track holds →
Short interest (FINRA)
LAB had 2,520,686 shares of reported short interest as of the 2026-09-30 FINRA settlement date (delayed, bi-monthly; not real-time).
LAB had 0.64% of its shares outstanding sold short as of the 2026-09-30 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 2.72 days to cover at the same settlement.
- Reported short interest (shares) 2,520,686
- Short interest (% of shares outstanding) 0.64%
- Prior settlement (shares) 2,593,308
- Reported change -2.8%
- Days to cover (reported) 2.72
Reported to FINRA as of the 2026-09-30 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- 10x Genomics (TXG)
- Bio-Rad Laboratories (BIO)
- Thermo Fisher Scientific (TMO)
- Danaher (DHR)
- Illumina (ILMN)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare LAB vs…
STANDARD BIOTOOLS INC. is found in…
LAB ranks in…
Frequently asked questions
What does STANDARD BIOTOOLS INC. (LAB) do?
Standard BioTools provides life science research tools, including instrumentation, consumables, and services, designed to assist biomedical researchers in drug discovery and translational research. Its portfolio includes platforms for proteomics and genomics, such as CyTOF and Hyperion, which allow researchers to generate high-content data across diverse therapeutic areas.
What sector is STANDARD BIOTOOLS INC. (LAB) in?
STANDARD BIOTOOLS INC. (LAB) is classified in the Health Care sector. Its industry is life science tools and services. It trades on NASDAQ.
Who are STANDARD BIOTOOLS INC.'s (LAB) competitors?
Notable peers of STANDARD BIOTOOLS INC. (LAB) include 10x Genomics, Bio-Rad Laboratories, Thermo Fisher Scientific, Danaher and Illumina. This peer set is informational only — not financial advice.
Is STANDARD BIOTOOLS INC. (LAB) overbought or oversold right now?
STANDARD BIOTOOLS INC. (LAB) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 40, in the neutral middle (as of 2026-10-20). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on LAB come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest; prices are market data, as of 2026-09-02; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-20.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.